BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6872338)

  • 1. Attachment of [35S]cysteine to the labile site of the third component of complement via the alternative pathway.
    Rutherford CJ; Alper CA; Rosen FS; Babior BM
    Clin Immunol Immunopathol; 1983 Jan; 26(1):76-82. PubMed ID: 6872338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent binding of [35S]cysteine to the labile binding site of the third component of complement: a physiological approach.
    Rutherford CJ; Jenkins DR
    Clin Immunol Immunopathol; 1985 Oct; 37(1):77-82. PubMed ID: 4028522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.
    Mann J; O'Brien R; Hostetter MK; Alper CA; Rosen FS; Babior BM
    J Immunol; 1981 Jun; 126(6):2370-2. PubMed ID: 6785350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3.
    Pangburn MK; Müller-Eberhard HJ
    Ann N Y Acad Sci; 1983; 421():291-8. PubMed ID: 6586103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibronectin binds to complement-coated agarose beads and increases their association to mouse macrophages.
    Johnson E; Gauperaa T; Eskeland T
    Scand J Immunol; 1985 Sep; 22(3):315-20. PubMed ID: 3876600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phagocytosis by human monocytes of particles activating the alternative pathway of complement.
    Johnson E; Eskeland T; Bertheussen K
    Scand J Immunol; 1984 Jan; 19(1):31-9. PubMed ID: 6701471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of the third component of human complement (C3) with tumour cells: evidence for presence of C3b acceptor sites and direct activation of C3 by tumour cells.
    Daveau M; Fontaine M; Gilbert D
    Ann Immunol (Paris); 1981; 132C(3):339-50. PubMed ID: 7332319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
    Gadd KJ; Reid KB
    Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the alternative pathway of complement by Malassezia ovalis (Pityrosporum ovale).
    Belew PW; Rosenberg EW; Jennings BR
    Mycopathologia; 1980 Mar; 70(3):187-91. PubMed ID: 6900183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall.
    Winkelstein JA; Abramovitz AS; Tomasz A
    J Immunol; 1980 May; 124(5):2502-6. PubMed ID: 7365262
    [No Abstract]   [Full Text] [Related]  

  • 14. Complement's alternate pathway.
    Ward AN
    Hosp Pract; 1979 Jun; 14(6):24. PubMed ID: 447326
    [No Abstract]   [Full Text] [Related]  

  • 15. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative pathway of complement activation by stimulated T lymphocytes. I. Binding of C3 fragments.
    Sármay G; Ramos OF; Klein E; Kai C; Gergely J
    Eur J Immunol; 1987 Jul; 17(7):969-74. PubMed ID: 3111862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volcanic ash and human complement.
    Olenchock SA; Mull JC
    Life Sci; 1981 Feb; 28(7):791-4. PubMed ID: 6262591
    [No Abstract]   [Full Text] [Related]  

  • 19. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.
    Edwards MS; Kasper DL; Jennings HJ; Baker CJ; Nicholson-Weller A
    J Immunol; 1982 Mar; 128(3):1278-83. PubMed ID: 7035562
    [No Abstract]   [Full Text] [Related]  

  • 20. Cleavage of C3 by a neutral cysteine proteinase of Entamoeba histolytica.
    Reed SL; Keene WE; McKerrow JH; Gigli I
    J Immunol; 1989 Jul; 143(1):189-95. PubMed ID: 2543700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.